The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
The researchers then analyzed the mood and emotional regulation capabilities of the participants during times…
The cannabis industry presents an array of high-paying job opportunities across various sectors—from finance and…
Recent studies have indicated a notable decrease in prescriptions for anti-anxiety medications, especially benzodiazepines, in…
We’ve assembled a list of fantastic brands and products from around the cannabis universe to…
If there's one thing I've learned from years of covering cannabis politics, it's that weed…
As we wrap up our deep dive into cannabis and exercise, I can't help but…